Cyclizine

Motion Sickness, Nausea and vomiting

Oral Motion Sickness, Nausea and vomiting Adult: As hydrochloride: 50 mg up to tid, up to 200 mg/day. For prevention of motion sickness, 1st dose should be given 30 min before traveling. May repeat in 4-6 hours if needed.

Oral Motion Sickness, Nausea and vomiting Child: 6-12 yr: As hydrochloride: 25 mg up to tid. Not to exceed 75 mg/day. For prevention of motion sickness, 1st dose should be given 30 min before traveling. >12 years: 50 mg PO taken 30 minutes before departure, may repeat in 4-6 hr if needed, up to 200 mg/day

HEPATIC IMPAIRMENT Advises caution.

Hypersensitivity Do not use in patients with asthma, glaucoma, emphysema, chronic pulmonary disease, shortness of breath, difficulty in breathing or difficulty in urination due to enlargement of the prostate gland unless directed by a doctor Cyclizine should not be used concurrently with sedatives, tranquilizers, or anticholinergic medications

Angle-closure glaucoma; urinary retention; prostatic hypertrophy; pyloroduodenal obstruction; epilepsy, severe CV disorders; known or suspected QT interval prolongation; hypokalaemia or other electrolyte imbalances; asthma; hepatic impairment. May have hypotensive effects, which may be confusing or dangerous in postoperative patients. May produce drowsiness; caution while driving or performing other tasks requiring alertness.

B

Enhanced sedative effects of alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics. Additive antimuscarinic actions with other antimuscarinic drugs and some antidepressants (TCAs and MAOIs). May mask ototoxicity symptoms caused by aminoglycoside antibiotics.

>10% Drowsiness Xerostomia 1-10% Headache Dermatitis Nausea Urinary retention Diplopia Polyuria

Cyclizine is a piperazine derivative that has antiemetic, anticholinergic, and antihistaminic properties; reduces the sensitivity of the labyrinthine apparatus and has central actions on the chemoreceptor trigger zone